Clinical trials
Every registered trial of Cagrilintide
68 studies, 11 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Cagrilintide has a real but limited body of human research.
- 68 registered studies in total.
- 11 are still enrolling people, so this is active research, not just history.
What kind of research
- 68 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 35,373 people took part in those.
How far along it is
- 21 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 9 have published results in the medical literature that anyone can read.
- The research spans 44 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 68 of 68 trials for Cagrilintide.
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Novo Nordisk A/S
Diabetes Mellitus, Type 2
NN9838-4968
Novo Nordisk A/S
Obesity and T2D
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Novo Nordisk A/S
Overweight · Obesity
NN9838-7910
Novo Nordisk A/S
Participants with obesity with or without type 2 diabetes
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
NN9833-8550
Novo Nordisk A/S
Participants with overweight or obesity
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Novo Nordisk A/S
Overweight · Obesity
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Novo Nordisk A/S
Obesity · Overweight
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk A/S
Obesity · Type 2 Diabetes
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
Novo Nordisk A/S
Overweight · Obesity
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
Novo Nordisk A/S
Obesity · Overweight
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
Novo Nordisk A/S
Overweight · Obesity
NN9833-8285
Novo Nordisk A/S
obesity
NN9833-8421
Novo Nordisk A/S
Obesity
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Novo Nordisk A/S
Obesity
NN9838-8411
Novo Nordisk A/S
Obesity, CCI, CCI
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
Novo Nordisk A/S
Overweight · Obese
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
Overweight · Obesity
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Novo Nordisk A/S
Obesity · Overweight
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Novo Nordisk A/S
Overweight · Obesity · Type 2 Diabetes
NN9833-8243
Novo Nordisk A/S
Overweight and obesity
NN9833-8242
Novo Nordisk A/S
Overweight and obesity
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Novo Nordisk A/S
Obesity
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Novo Nordisk A/S
Obesity
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk A/S
Obesity
NN9388-8175
Novo Nordisk A/S, Steno Diabetes Center Copenhagen
Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Novo Nordisk A/S
Obesity
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Novo Nordisk A/S
Diabetes Mellitus, Type 2 · Diabetic Peripheral Neuropathy
NN9838-7859
Novo Nordisk A/S
Obesity
NN9388-7864
Novo Nordisk A/S
Type 2 diabetes and painful diabetic peripheral neuropathy
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Novo Nordisk A/S
Obesity · Overweight
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Novo Nordisk A/S
Obesity
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk A/S
Diabetes Mellitus, Type 2
NN9388-7741
Novo Nordisk A/S
Type 2 Diabetes
NN9838-7749
Novo Nordisk A/S
Obesity
NN9500-7730
Novo Nordisk A/S
alcohol-related liver disease
NN9388-4895
Novo Nordisk A/S
Type 2 diabetes
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S
Obesity
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Novo Nordisk A/S
Alcohol-related Liver Disease
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
Novo Nordisk A/S
Diabetes Mellitus, Type 2
NN9388-7782
Novo Nordisk A/S
Type 2 diabetes
NN9388-7700
Novo Nordisk A/S
Chronic Kidney Disease, Type 2 diabetes
NN9388-7637
Novo Nordisk A/S
Type 2 diabetes
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Novo Nordisk A/S
Chronic Kidney Disease · Type 2 Diabetes · Obesity
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Novo Nordisk A/S
Type 2 Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk A/S
Type 2 Diabetes
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Novo Nordisk A/S
Obesity
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
Novo Nordisk A/S
Obesity
NN9838-4695
Novo Nordisk A/S
Obesity
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Novo Nordisk A/S
Overweight · Obesity
NN9838-4944
Novo Nordisk A/S
Obesity
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S
Type 2 Diabetes
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Novo Nordisk A/S
Obesity
NN9388-4896
Novo Nordisk A/S
Type 2 diabetes
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
Novo Nordisk A/S
Obesity or Overweight
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
Novo Nordisk A/S
Obesity
A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
Novo Nordisk A/S
Hepatic Impairment · Healthy Volunteers
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Novo Nordisk A/S
Obesity or Overweight
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Novo Nordisk A/S
Cardiovascular Disease
NN9838-4942
Novo Nordisk A/S
Cardiovascular disease
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Novo Nordisk A/S
Overweight · Obesity · Type 2 Diabetes Mellitus
NN9838-4609
Novo Nordisk A/S
Overweight and obesity and type 2 diabetes
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S
Obesity
NN9838-4608
Novo Nordisk A/S
Overweight and obesity
NN9500-4656
Novo Nordisk A/S
Non-alcoholic steatohepatitis (NASH)
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
Novo Nordisk A/S
Obesity & Overweight
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Cagrilintide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.